NCT06492109 The Peripheral Blood Multi-Omics Study on Sleep Loss
| NCT ID | NCT06492109 |
| Status | Recruiting |
| Phase | — |
| Sponsor | First Affiliated Hospital of Zhejiang University |
| Condition | Sleep Deprivation |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2024-06-20 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2024-06-20 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Sleep plays a role in cognitive processes such as memory processing, attention processing, and overall cognitive function. In recent years, the bidirectional relationship between sleep loss and aging, as well as related neurodegenerative diseases, has garnered widespread attention. Sleep disorders are a typical clinical manifestation of neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease and are closely related to the progression of these diseases. However, current research has yet to fully elucidate the physiological responses to sleep loss across different ages and cognitive levels, as well as the association and molecular basis between sleep loss, aging, and neurodegenerative diseases. This study aims to comprehensively characterize the transcriptional and metabolic changes in peripheral blood under sleep loss in populations of different ages and cognitive levels using multi-omics approaches and to preliminarily explore the role of sleep loss in aging and AD.
Eligibility Criteria
Inclusion Criteria: 1. Signed informed consent form； 2. Meet the inclusion criteria for each arms. Exclusion Criteria: 1. Failure to provide informed consent; 2. Inability to follow study procedures due to issues such as language barriers or cognitive impairment; 3. Regular use of medications that may alter the relationship between sleep and outcome variables (e.g., opioid medications, benzodiazepines, and Z drugs \[non-benzodiazepine hypnotics\]); 4. History of alcohol abuse, substance abuse, consciousness disorders, cerebrovascular disease, head injury, epilepsy, encephalitis, or other neurological disorders; 5. Diagnosis of schizophrenia, severe depression, anxiety disorders, or other severe psychiatric conditions; 6. Presence of severe arrhythmias, myocardial infarction within the last 6 months, severe pulmonary dysfunction, renal or hepatic insufficiency, severe anemia, severe gastrointestinal diseases, tumors, or other severe medical conditions.
Contact & Investigator
Benyan Luo
PRINCIPAL INVESTIGATOR
Zhejiang University
Frequently Asked Questions
Who can join the NCT06492109 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Sleep Deprivation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06492109 currently recruiting?
Yes, NCT06492109 is actively recruiting participants. Contact the research team at luobenyan@zju.edu.cn for enrollment information.
Where is the NCT06492109 trial being conducted?
This trial is being conducted at Hangzhou, China.
Who is sponsoring the NCT06492109 clinical trial?
NCT06492109 is sponsored by First Affiliated Hospital of Zhejiang University. The principal investigator is Benyan Luo at Zhejiang University. The trial plans to enroll 60 participants.